Skip to main content
Premium Trial:

Request an Annual Quote

ImmusanT Nabs $12M Investment to Support Celiac Disease CDx and Immunotherapy

NEW YORK (GenomeWeb) – ImmusanT today announced it has raised $12 million in Series B financing from Vatera Healthcare Partners to continue developing Nexvax2, an immunotherapy for celiac disease, as well as a companion diagnostic to pair with the treatment and a standalone blood-based diagnostic.

The Cambridge, Mass.-based firm will continue to develop its whole-blood functional T-cell test as both a companion diagnostic to identify patients most likely to respond to Nexvax2 and as a standalone test.

Nexvax2 is an adjuvant-free, disease-modifying immunotherapy for celiac disease that reprograms a patient's immune system to tolerate gluten in the diet. It is comprised solely of three gluten-derived peptides in saline that are responsible for the immune reaction that causes celiac disease. ImmusanT recently completed two Phase 1b studies to demonstrate safety, tolerability, and bioactivity of Nexvax2, and Phase II trials will begin in early 2015, the firm said in a statement.

The funding follows $20 million that ImmusanT received from Vatera in 2011 for the development of celiac diagnostic tools.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.